Moleculin Biotech, Inc. (MBRX) company profile
Close on Nov 18, 2026Market cap $131.47MP/E –Yield –
About Moleculin Biotech
Pharmaceutical Preparations, SIC 2834
Moleculin Biotech is a late-stage pharmaceutical development company focused on creating treatments for hard-to-treat oncology indications and viruses. The company's lead drug candidate is Annamycin, a next-generation anthracycline designed to avoid cardiotoxicity and bypass multidrug resistance mechanisms. Its clinical pipeline also includes the WP1066 program targeting glioblastoma and other brain tumors, as well as the WP1122 portfolio of glycolysis inhibitors. Core clinical candidates serve patient populations with acute myeloid leukemia, soft tissue sarcoma lung metastases, and pediatric brain cancers.
The company operates internationally, coordinating research and clinical programs across academic institutions and medical centers in the United States and Europe. Its clinical trials include multi-center evaluations spanning over twenty sites across nine countries, such as Poland, Italy, and the United States. Key preclinical and development collaborations take place in conjunction with the University of Texas MD Anderson Cancer Center in Houston, Texas. Moleculin Biotech does not specify its corporate headquarters location in the provided text.
Summary of the business section of Moleculin Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Moleculin Biotech, Inc.
- Headquarters
- Houston, TX
- Address
- 5300 Memorial Drive, Suite 950 77007
- Phone
- (713) 300-5160
- Website
- moleculin.com
- Employees
- 150,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Fort Lauderdale, Florida
Stock & identifiers
- Ticker
- MBRX
- Exchange
- Nasdaq
- IPO date
- May 3, 2016
- Shares outstanding
- 19M, Aug 6, 2026
- Public float
- $8.80M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Oct 20, 2026; 1-for-25 reverse, Dec 1, 2025; 1-for-15 reverse, Mar 22, 2024; 1-for-6 reverse, Feb 1, 2021
- SEC CIK
- 1659617
- CUSIP
- 60855D408
- ISIN
- US60855D4088
- FIGI
- BBG00B9T47L9
- Share class FIGI
- BBG00B9T47N7
- LEI
- 549300IB1TLJZCHEO353
- EIN
- 47-4671997
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Walter V. Klemp | CEO and President, Director | 1,111,545 |
| Jonathan P. Foster | Chief Financial Officer | 20,506 |
| Donald H. Picker | Chief Science Officer | 560,718 |
| John M. Climaco | Director | – |
| Michael D. Cannon | Director | – |
| Robert E. George | Director | 14,660 |
| Elizabeth Cermak | Director | – |
| Joy Yan | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.35M | $722.26K | $765.09K | $1 | – |
| FY2024 | $1.46M | $339.60K | $841.85K | $11 | – |
| FY2023 | $1.41M | $1.44M | $719.87K | $81 | – |
| FY2022 | $1.97M | $1.46M | $895.86K | $22 | – |
| FY2021 | $1.99M | $754.19K | $915.79K | $39 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Walter V. Klemp Chairman, President - Chief Executive Officer | $565.00K | $324.89K | $426.75K | $29.32K | $1.35M | -8% |
| Jonathan P. Foster Executive Vice President and Chief Financial Officer | $405.00K | $234.86K | $227.60K | $39.81K | $907.27K | -8% |
| Donald Picker Chief Scientific Officer | $340.00K | $78.23K | $182.08K | $22.61K | $622.92K | -10% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 3, 2016
- Offer price
- $6.00
- Securities offered
- 2,000,000
- Gross proceeds
- $12.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Oct 30, 2016
“The initial public offering price per share will be $6.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“There are approximately 150,000 people with AML worldwide with over 20,000 newly diagnosed patients annually in the U.S.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?